JP2003510257A - カッパ−コノトキシンｐｖｉｉａの使用 - Google Patents

カッパ−コノトキシンｐｖｉｉａの使用

Info

Publication number
JP2003510257A
JP2003510257A JP2001525222A JP2001525222A JP2003510257A JP 2003510257 A JP2003510257 A JP 2003510257A JP 2001525222 A JP2001525222 A JP 2001525222A JP 2001525222 A JP2001525222 A JP 2001525222A JP 2003510257 A JP2003510257 A JP 2003510257A
Authority
JP
Japan
Prior art keywords
cys
lys
asn
arg
gln
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001525222A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003510257A5 (enExample
Inventor
アン・エイチ・コーネル−ベル
カレン・イー・ペンバートン
デイビス・エル・テンプル・ジュニア
リチャード・ティ・レイヤー
アール・タイラー・マッケイブ
ロバート・アール・ジョーンズ
Original Assignee
コグネティックス・インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by コグネティックス・インコーポレイテッド filed Critical コグネティックス・インコーポレイテッド
Publication of JP2003510257A publication Critical patent/JP2003510257A/ja
Publication of JP2003510257A5 publication Critical patent/JP2003510257A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2001525222A 1999-09-22 2000-09-21 カッパ−コノトキシンｐｖｉｉａの使用 Pending JP2003510257A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US15513599P 1999-09-22 1999-09-22
US60/155,135 1999-09-22
US21943800P 2000-07-20 2000-07-20
US60/219,438 2000-07-20
PCT/US2000/025827 WO2001021648A1 (en) 1999-09-22 2000-09-21 Uses of kappa-conotoxin pviia

Publications (2)

Publication Number Publication Date
JP2003510257A true JP2003510257A (ja) 2003-03-18
JP2003510257A5 JP2003510257A5 (enExample) 2007-11-01

Family

ID=26852034

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001525222A Pending JP2003510257A (ja) 1999-09-22 2000-09-21 カッパ−コノトキシンｐｖｉｉａの使用

Country Status (6)

Country Link
US (2) US20040092447A1 (enExample)
EP (1) EP1218407A4 (enExample)
JP (1) JP2003510257A (enExample)
AU (1) AU778182B2 (enExample)
CA (1) CA2385047A1 (enExample)
WO (1) WO2001021648A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003533178A (ja) 1999-12-30 2003-11-11 ユニバーシティ・オブ・ユタ・リサーチ・ファウンデーション Ｏ−スーパーファミリー・コノトキシンペプチド
AUPR506601A0 (en) * 2001-05-17 2001-06-07 Australian National University, The Method of modulating the activity of calcium channels in cardiac cells and reagents therefor
US20030224343A1 (en) * 2002-01-29 2003-12-04 University Of Utah Research Foundation Kappa-PVIIA-related conotoxins as organ protectants
US20040229780A1 (en) * 2002-09-20 2004-11-18 Olivera Baldomero M. KappaM-conopeptides as organ protectants
US20060178303A1 (en) * 2004-09-09 2006-08-10 University Of Utah Research Foundation Potassium channel blockers
US10531655B2 (en) 2011-12-02 2020-01-14 The Regents Of The University Of California Reperfusion protection solution and uses thereof
CN107074909B (zh) * 2014-09-30 2020-11-27 深圳华大基因科技有限公司 芋螺毒素多肽κ-CPTx-btl01、其制备方法及应用
EP3202782B1 (en) * 2014-09-30 2019-10-16 BGI Shenzhen Co., Limited Conotoxin polypeptide kappa-cptx-bt103, and method for preparation thereof and application thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997034925A1 (en) * 1996-03-18 1997-09-25 University Of Utah Research Foundation Conotoxin peptide pviia
WO1999037607A1 (en) * 1998-01-27 1999-07-29 Icagen, Inc. Potassium channel inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997034925A1 (en) * 1996-03-18 1997-09-25 University Of Utah Research Foundation Conotoxin peptide pviia
WO1999037607A1 (en) * 1998-01-27 1999-07-29 Icagen, Inc. Potassium channel inhibitors

Also Published As

Publication number Publication date
US20040092447A1 (en) 2004-05-13
EP1218407A4 (en) 2003-01-08
AU778182B2 (en) 2004-11-18
WO2001021648A1 (en) 2001-03-29
US20060040312A1 (en) 2006-02-23
CA2385047A1 (en) 2001-03-29
EP1218407A1 (en) 2002-07-03
AU7596800A (en) 2001-04-24

Similar Documents

Publication Publication Date Title
US20080089844A1 (en) Kappam-conopeptides as organ protectants
CA1341060C (en) Use of amylin agonists in the treatment of diabetes mellitus
EP0835126B1 (en) Compositions and formulations for producing analgesia and for inhibiting progression of neuropathic pain disorders
JP5558817B2 (ja) 痛みの処置方法および鎮痛化合物のスクリーニング方法
US6680295B1 (en) Method and pharmaceutical composition for prevention and treatment of brain damage
JP2004537253A (ja) ミュー−コノペプチド
US8101573B2 (en) α-conotoxin MII analogs
US20060257843A1 (en) Kappa-PVIIA-related conotoxins as organ protectants
AU778182B2 (en) Uses of kappa-conotoxin PVIIA
WO2002002630A2 (en) Hcn polypeptides and polynucleotides and their use in therapy
EP2580233B1 (en) Materials and method for suppressing inflammatory and neuropathic pain
WO1993010145A1 (en) Compositions for delayed treatment of ischemia-related neuronal damage
US20050214903A1 (en) O-superfamily conotoxin peptides
JP2004512025A (ja) オメガ−コノペプチド
US20050096270A1 (en) I-superfamily conotoxins
AU2003209395A1 (en) Kappa-PVIIA-related conotoxins as organ protectants
US20080274976A1 (en) Uses of novel potassium channel blockers
US20040259794A1 (en) MuO-conopeptides and their use as local anesthetics
WO2002007756A1 (en) MuO-CONOPEPTIDES AND THEIR USE AS LOCAL ANESTHETICS
US20030119731A1 (en) Omega-conopeptides
Burt 9 10 11 Maura L. Cotter, Scott Boitano, Josef Vagner 3, 4, and Janis M. Burt 12 13

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070911

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070911

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20080911

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101005

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110315